Washington, D.C.—The Natural Products Association (NPA) recently installed Daniel Fabricant, Ph.D., as its new executive director and CEO. He returns to NPA after serving as the director of the Division of Dietary Supplement Programs at the U.S. Food and Drug Administration (FDA) for three years.
On the beautiful afternoon of April 8 in Washington, D.C., the Natural Products Association (NPA) held its 17th annual Natural Products Day. The event is designed to allow retailers and other natural products industry stakeholders to lobby their elected representatives on behalf of the industry’s interests.
Washington, D.C.—The Council for Responsible Nutrition (CRN) issued a statement regarding a study that found a diet rich in polyunsaturated fats and low in saturated fats does not provide heart health benefits.
Austin, TX—The American Botanical Council’s (ABC) 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award has been presented to Wakunaga Pharmaceutical Company, LLC (Osaka, Japan). Wakunaga is the maker of Kyolic Aged Garlic Extract.
Washington, D.C.—The National Products Association (NPA), based here, has announced that Daniel Fabricant, Ph.D., will be its new chief executive officer (CEO) and executive director. Fabricant had previously served as the U.S. Food and Drug Administration’s Director of the Division of Dietary Supplement Programs for three years.
In a presentation and panel discussion moderated by WholeFoods editor/associate publisher Kaylynn Chiarello-Ebner, several experts shared perspectives on the use of natural versus synthetic astaxanthin. A carotenoid naturally found in microalgae, astaxanthin is known as a potent antioxidant.
Washington, D.C.—The Federal Trade Commission (FTC) has won $2.2 million it its lawsuit against supplement maker Wellness Support Network Inc. (WSN) for making false or unsupported claims about its diabetes supplements.
Jarrow L. Rogovin, president of dietary supplements manufacturer Jarrow Formulas, Inc., based in Los Angeles, CA, is seeking answers about some recent practices at the U.S. Food and Drug Administration (FDA).